# EDGAR Filing Document

**Accession Number:** 0001811623
**File Stem:** 0001641172-25-015071
**Filing Date:** 2025-6
**Character Count:** 3123
**Document Hash:** 24b14e0315dbd41d93c6db224840ea4e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-015071.hdr.sgml**: 20250613

**ACCESSION NUMBER**: 0001641172-25-015071

**CONFORMED SUBMISSION TYPE**: 15-12G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250613

**DATE AS OF CHANGE**: 20250613

**EFFECTIVENESS DATE**: 20250613

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PaxMedica, Inc.
- **CENTRAL INDEX KEY:** 0001811623
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 15-12G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41475
- **FILM NUMBER:** 251046552

**BUSINESS ADDRESS:**
- **STREET 1:** 303 SOUTH BROADWAY, SUITE 125
- **CITY:** TARRYTOWN
- **STATE:** NY
- **ZIP:** 10591
- **BUSINESS PHONE:** 914-987-2876

**MAIL ADDRESS:**
- **STREET 1:** 303 SOUTH BROADWAY, SUITE 125
- **CITY:** TARRYTOWN
- **STATE:** NY
- **ZIP:** 10591

---

| | |
|:---|:---|
|  | OMB APPROVAL |
| **UNITED STATES**<br> **SECURITIES AND EXCHANGE COMMISSION** | OMB Number: 3235-0167<br> Expires: August 31, 2027<br> Estimated average burden<br> hours per response 1.50  |
| **Washington, D.C. 20549** |  |

---

**FORM 15**

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER<br> SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION<br> OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE<br> SECURITIES EXCHANGE ACT OF 1934.**

Commission File Number **<u>001-41475</u>**

**Kuvatris Therapeutics, Inc. (formerly PaxMedica, Inc.)**

(Exact name of registrant as specified in its charter)

1000 Wyckoff Avenue, 3<sup>rd</sup> Floor, Mahwah, NJ 07430

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

Common Stock, par value $0.0001 per share

(Title of each class of securities covered by this Form)

N/A

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

---

| | |
|:---|:---|
| Rule 12g-4(a)(1) | ☒ |
| Rule 12g-4(a)(2) | ☐ |
| Rule 12h-3(b)(1)(i) | ☐ |
| Rule 12h-3(b)(1)(ii) | ☐ |
| Rule 15d-6 | ☒ |
| Rule 15d-22(b) | ☐ |

---

Approximate number of holders of record as of the certification or notice date: <u>13</u> 

Pursuant to the requirements of the Securities Exchange Act of 1934 (Name of registrant as specified in charter) has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

---

| | | | |
|:---|:---|:---|:---|
| Date: | 6-13-2025 | By: | */s/ Howard J. Weisman*  |

---

SEC 2069 (08-11) Potential persons who are to respond to the collection of information contained in this Form are not required to respond unless the Form displaces a currently valid OMB control number.

Board of Governors of the Federal Reserve System OMB Number 7100-0091 Approval expires February 28, 2026